Translational metabolomics in cancer research

Biomarkers in Medicine

Volumn 9, Issue 9, 2015, Pages 821-834

  Snyder, Nathaniel W ^a,b   Mesaros, Clementina ^a   Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DREXEL UNIVERSITY   (United States)

Author keywords

cancer; cancer diagnosis; diagnostic biomarkers; lipidomics; liquid chromatography mass spectrometry; NMR spectroscopy; prognostic biomarkers; untargeted metabolomics targeted metabolomics

Indexed keywords

TUMOR MARKER;

BREAST CANCER; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; COLORECTAL CANCER; EARLY DIAGNOSIS; GAS CHROMATOGRAPHY; HUMAN; LEUKEMIA; LIQUID CHROMATOGRAPHY; LUNG CANCER; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PANCREAS CANCER; PROSTATE CANCER; REVIEW; TRANSLATION REGULATION; VALIDATION PROCESS; METABOLISM; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROCEDURES; TRANSLATIONAL RESEARCH;

HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84942876036     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.52     Document Type: Review

References (41)

1. O'Connell TM. Recent advances in metabolomics in oncology. Bioanalysis 4(4), 431-451 (2012).
2. Blair IA. Bioanalysis supporting disease biomarker discovery and validation. In: Eliminating Bottlenecks for Efficient Bioanalysis: Practices and Applications in Drug Discovery and Development. Future Science Group, London, UK, 162-181 (2015).
3. Blair IA. Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 75(4-5), 297-306 (2010).
4. Lei Z, Huhman DV, Sumner LW. Mass spectrometry strategies in metabolomics. J. Biol. Chem. 286(29), 25435-25442 (2011).
5. Forcisi S, Moritz F, Kanawati B, Tziotis D, Lehmann R, Schmitt-Kopplin P. Liquid chromatography-mass spectrometry in metabolomics research: mass analyzers in ultra high pressure liquid chromatography coupling. J. Chromatogr. A 1292, 51-65 (2013).
6. Milne SB, Mathews TP, Myers DS, Ivanova PT, Brown HA. Sum of the parts: mass spectrometry-based metabolomics. Biochemistry 52(22), 3829-3840 (2013).
7. Zhang T, Watson DG, Wang L et al. Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery. PLoS One 8(6), e65880 (2013).
8. Barding GA Jr, Salditos R, Larive CK. Quantitative NMR for bioanalysis and metabolomics. Anal. Bioanal. Chem. 404(4), 1165-1179 (2012).
9. Smolinska A, Blanchet L, Buydens LM, Wijmenga SS. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal. Chim. Acta 750, 82-97 (2012).
10. Ciccimaro E, Blair IA. Stable-isotope dilution LC-MS for quantitative biomarker analysis. Bioanalysis 2(2), 311-341 (2010).
11. Fan TW, Lane AN, Higashi RM et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13) C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 8, 41 (2009).
12. Lane AN, Fan TW, Bousamra M, Higashi RM, Yan J, Miller DM. Stable isotope-resolved metabolomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer. OMICS 15(3), 173-182 (2011).
13. Basu SS, Deutsch EC, Schmaier AA, Lynch DR, Blair IA. Human platelets as a platform to monitor metabolic biomarkers using stable isotopes and LC-MS. Bioanalysis 5(24), 3009-3021 (2013).
14. Moore HM, Compton CC, Lim MD, Vaught J, Christiansen KN, Alper J. 2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. Cancer Res. 69(17), 6770-6772 (2009).
15. Kumar S, Huang J, Abbassi-Ghadi N, Spanel P, Smith D, Hanna GB. Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. Anal. Chem. 85(12), 6121-6128 (2013).
16. Serkova NJ, Spratlin JL, Eckhardt SG. NMR-based metabolomics: translational application and treatment of cancer. Curr. Opin. Mol. Ther. 9(6), 572-585 (2007).
17. Gulston MK, Rubtsov DV, Atherton HJ et al. A combined metabolomic and proteomic investigation of the effects of a failure to express dystrophin in the mouse heart. J. Proteome. Res. 7(5), 2069-2077 (2008).
18. Karakach TK, Wentzell PD, Walter JA. Characterization of the measurement error structure in 1D 1H NMR data for metabolomics studies. Anal. Chim. Acta 636(2), 163-174 (2009).
19. Zhou J, Xu B, Huang J et al. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clin. Chim. Acta 401(1-2), 8-13 (2009).
20. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem. Res. Toxicol. 21(1), 9-27 (2008).
21. Snyder NW, Khezam M, Mesaros CA, Worth A, Blair IA. Untargeted metabolomics from biological sources using ultraperformance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS). J. Vis. Exp. 75, e50433 (2013).
22. Trock BJ. Application of metabolomics to prostate cancer. Urol. Oncol. 29(5), 572-581 (2011).
23. DeFeo EM, Wu CL, McDougal WS, Cheng LL. A decade in prostate cancer: from NMR to metabolomics. Nat. Rev. Urol. 8(6), 301-311 (2011).
24. Koutros S, Meyer TE, Fox SD et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the prostate, lung, colorectal and ovarian cancer screening trial. Carcinogenesis 34(10), 2281-2285 (2013).
25. de Vogel S., Ulvik A, Meyer K et al. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer-a large nested case-control study within the JANUS cohort in Norway. Int. J. Cancer 134(1), 197-206 (2014).
26. Weljie AM, Bondareva A, Zang P, Jirik FR. (1)H NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system. J. Biomol. NMR 49(3-4), 185-193 (2011).
27. Budczies J, Brockmoller SF, Muller BM et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J. Proteomics 94, 279-288 (2013).
28. Wei S, Liu L, Zhang J, Bowers J et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol. Oncol. 7(3), 297-307 (2013).
29. Zhang AH, Sun H, Qiu S, Wang XJ. Metabolomics in noninvasive breast cancer. Clin. Chim. Acta 424, 3-7 (2013).
30. Wang Q, Rangiah K, Mesaros C et al. Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography-tandem mass spectrometry. Steroids 96, 140-152 (2015).
31. Mauras N, Santen RJ, Colon-Otero G et al. Estrogens and their genotoxic metabolites are increased in obese prepubertal girls. J. Clin. Endocrinol. Metab. 100(6), 2322-2228 (2015).
32. Zhang A, Sun H, Yan G, Wang P, Han Y, Wang X. Metabolomics in diagnosis and biomarker discovery of colorectal cancer. Cancer Lett. 345(1), 17-20 (2014).
33. Ritchie SA, Ahiahonu PW, Jayasinghe D et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 8, 13 (2010).
34. Nishiumi S, Kobayashi T, Ikeda A et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 7(7), e40459 (2012).
35. Bathe OF, Shaykhutdinov R, Kopciuk K et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol. Biomarkers Prev. 20(1), 140-147 (2011).
36. Kobayashi T, Nishiumi S, Ikeda A et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 22(4), 571-579 (2013).
37. DiNardo CD, Propert KJ, Loren AW et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121(24), 4917-4924 (2013).
38. Mesaros C, Worth A, Snyder NW et al. Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure. Bioanalysis 7(9), 1157-1173 (2015).
39. Fahy E, Subramaniam S, Murphy RC et al. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 50(Suppl.), S9-S14 (2009).
40. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13(6), 472-482 (2008).
41. Dang CV. Links between metabolism and cancer. Genes Dev. 26(9), 877-890 (2012).